Fantastic.
Avexa Reports Superior Results in ATC Phase IIb Clinical Trial Update.
48 week data shows 90% of treated patients achieve undetectable viral loads
Key Highlights from the 48 week data.
• Increase in the percentage of patients with viral loads below detectable at week 48 compared to week
24